News Search Results
Apr 14, 2025, 08:00 ET Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for CAR-T Technology, Further Strengthening its Robust Intellectual Property Portfolio
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has received a Notice of Allowance from the United States Patent
More news about: Anixa Biosciences, Inc.
Apr 14, 2025, 08:00 ET Torrey Pines Law Group Recognized as a Leading Intellectual Property Law Firm by Chambers USA California Spotlight Guide 2025
transactions, and FDA regulatory compliance. The firm partners with technology innovators across industries such as artificial intelligence (AI), biotechnology, pharmaceuticals, diagnostics, digital health, medical devices, semiconductors, software, telecommunications, and wireless technologies. With offices
More news about: Torrey Pines Law Group
Apr 14, 2025, 07:30 ET Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks
procurement contracts with the U.S. Government or other countries, that it will be able to compete with larger and better financed competitors in the biotechnology industry, that changes in health care practice, third party reimbursement limitations and Federal and/or state health care reform initiatives will
More news about: SOLIGENIX, INC.
Apr 14, 2025, 06:51 ET Ferulic Acid Market to Reach $104.2 Mn by 2027 in the short run and 167.1 Mn by 2035 globally, at 6% CAGR: Allied Market Research
report include Tokyo Chemical Industry Co., Ltd., Aktin Chemicals Inc., Pfaltz and Bauer, Inc., Spectrum Chemical Manufacturing Corp., Tianjin NWC Biotechnology Co., Ltd., Chemfaces, Sigma-Aldrich Corporation, Nomura Chemical Co., Ltd., and Merck KgaA. Explore AMR's Extensive ongoing Coverage on
More news about: Allied Market Research
Apr 14, 2025, 05:00 ET Chromatin Bioscience Signs Collaboration Agreement with Astellas
Bioscience. "We believe the ability to precisely control targeted gene expression is becoming increasingly critical across diverse applications in biotechnology. This collaboration reflects the growing interest in synthetic promoter technology as a key enabler in the development of precision-targeted biological
More news about: Chromatin Bioscience
Apr 14, 2025, 05:00 ET Chromatin Bioscience Signs Collaboration Agreement with Astellas
Bioscience. "We believe the ability to precisely control targeted gene expression is becoming increasingly critical across diverse applications in biotechnology. This collaboration reflects the growing interest in synthetic promoter technology as a key enabler in the development of precision-targeted biological
More news about: Chromatin Bioscience
Apr 14, 2025, 03:00 ET PRISM BioLab and Elix Join Forces to Accelerate AI-Driven Drug Discovery for Protein-Protein Interaction Targets
April 14, 2025 /PRNewswire/ -- PRISM BioLab, Co. Ltd. ("PRISM BioLab"), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that it has entered into a drug discovery
More news about: PRISM BioLab Co., Ltd.
Apr 13, 2025, 09:03 ET SANA Investors Have Opportunity to Lead Sana Biotechnology, Inc. Securities Fraud Lawsuit
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sana Biotechnology, Inc. (NASDAQ: SANA) between March 17, 2023 and November 4, 2024, both dates inclusive
More news about: THE ROSEN LAW FIRM, P. A.
Apr 11, 2025, 13:00 ET WesternU COMP and COMP-Northwest named Tier 1 medical school for primary care for second consecutive year
Calif. and Lebanon, Ore., is an independent nonprofit health professions university, conferring degrees in biotechnology and pharmaceutical sciences, dental medicine, medical sciences, nursing, optometry, osteopathic medicine, pharmacy, physical therapy, physician
More news about: Western University of Health Sciences
Apr 11, 2025, 12:31 ET Global Times: Believing in China, believing in tomorrow
China's action.From launching pilot projects to expand opening-up in the fields of value-added telecommunications and biotechnology, to support domestic and foreign-funded enterprises equally in participating in large-scale equipment upgrades, consumer goods trade-in and other
More news about: Global Times
Apr 11, 2025, 10:23 ET ZINZINO AB (PUBL.): Zinzino acquires Valentus Global to increase distribution power in Europe
strategically important step in Zinzino's growth plans, which focus on improving personal health and well-being on a global scale with innovative biotechnology and a pioneering product portfolio marketed through direct sales. Valentus Global Inc. is a direct selling company based in Delaware,
More news about: Zinzino
Apr 11, 2025, 10:13 ET ZINZINO AB (PUBL.): Zinzino acquires Valentus Global to increase distribution power in Europe
strategically important step in Zinzino's growth plans, which focus on improving personal health and well-being on a global scale with innovative biotechnology and a pioneering product portfolio marketed through direct sales. Valentus Global Inc. is a direct selling company based in Delaware,
More news about: Zinzino
Apr 11, 2025, 09:00 ET IMDELLTRA® DEMONSTRATED SUPERIOR OVERALL SURVIVAL IN SMALL CELL LUNG CANCER
to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing
More news about: Amgen
Apr 11, 2025, 08:00 ET Novonesis Poised to Accelerate National Security Commission Priorities on Biotechnology
importance of the National Security Commission on Emerging Biotechnology (NSCEB) report as a pivotal milestone in charting a bold path forward for American biotechnology. Novonesis applauds the NSCEB's deep investigation of unlocking U.S.-led biotechnology in the Fourth Industrial Revolution.
More news about: Novonesis
Apr 11, 2025, 05:45 ET Class Action Filed Against Sana Biotechnology, Inc. (SANA) Seeking Recovery for Investors - Contact Levi & Korsinsky
April 11, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sana Biotechnology, Inc. ("Sana Biotechnology, Inc." or the "Company") (NASDAQ: SANA) of a class action securities lawsuit.
More news about: Levi & Korsinsky, LLP
Apr 11, 2025, 05:45 ET Class Action Filed Against ICON Public Limited Company (ICLR) Seeking Recovery for Investors - Contact Levi & Korsinsky
insufficient to shield the Company from the adverse effects of a significant market downturn; (c) the requests for proposals ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand;
More news about: Levi & Korsinsky, LLP
Apr 10, 2025, 22:22 ET CCV Capital's Founding Managing Partner Wei Zhou Attends the 2025 Harvard College China Forum
political, and academic communities worldwide gathered to engage in in-depth discussions on frontier topics such as international relations, economics, biotechnology, and artificial intelligence. Distinguished guests included Kevin Rudd, former Prime Minister of Australia;
More news about: CCV Capital
Apr 10, 2025, 18:15 ET Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy
commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and
More news about: Halozyme Therapeutics, Inc.
Apr 10, 2025, 18:09 ET Oncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital
qualification under the securities laws of any such jurisdiction. About Oncolytics Biotech Inc. Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized
More news about: Oncolytics Biotech® Inc.
Apr 10, 2025, 13:09 ET Oerth Bio Publishes Landmark Study Demonstrating the First Application of PROTACs in Agriculture
more selective, environmentally friendly, and overcome current resistance challenges. "Oerth Bio's work demonstrates how cutting-edge biotechnology platforms can be reimagined to solve some of agriculture's most urgent challenges. This publication is a key proof point for Leaps by Bayer's mission
More news about: Oerth Bio
Apr 10, 2025, 13:00 ET Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
Immunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today
More news about: Immunic, Inc.
Apr 10, 2025, 12:14 ET Professor Niazi Challenges the 2024 Chemistry Nobel Prize that the 3D Protein Structure cannot be predicted, refuting claims of Rosetta and AlphaFold
Quantum mechanics paradox in protein structure prediction: Intrinsically linked to sequence yet independent of it, Computational and Structural Biotechnology Reports, Volume 2, 2025, 100039, ISSN 2950-3639, https://doi.org/10.1016/j.csbr.2025.100039.
More news about: Professor Sarfaraz K. Niazi
Apr 10, 2025, 12:00 ET ICON plc (ICLR) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
offerings were insufficient to shield the Company from the adverse effects of a significant market downturn; (3) that the RFPs ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand;
More news about: Glancy Prongay & Murray LLP
Apr 10, 2025, 11:28 ET Rubin and Rudman Elevates Lauren DeMatteo to Partner
Rubin and Rudman serves national and international companies, including large public companies and closely held businesses; real estate developers; biotechnology, pharmaceutical and medical device makers; regulated industries, public entities and municipalities; insurance companies and their insureds; educational
More news about: Rubin and Rudman
Apr 10, 2025, 10:01 ET Global Organ on a Chip Market Valuation is Poised to Surpass 2,238.28 Million by 2033 | Astute Analytica
DiscoveryToxicology ResearchOthersBy End Users Academic and Research InstitutesPharmaceutical & Biotechnology CompaniesOthersBy Region North AmericaEurope
More news about: Astute Analytica